Clinical Trial Update: Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Tg01 Vaccine with QS-21 Stimulon, with or without balstilimab, as maintenance therapy after adjuvant chemotherapy in patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Balstilimab (balstilimab)
• QS-21 Stimulon (QS-21 Stimulon)
• Tg01 Vaccine

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Pancreas Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING